Pegylated interferons

Clinics in Liver Disease

Volumn 7, Issue 1, 2003, Pages 139-148

  Karnam, Umaprasanna S ^a   Reddy, K Rajender ^b  

^a Central Utah Medical Clinic   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; MACROGOL; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; REBETRON; RIBAVIRIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MIXTURE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEPATITIS C; HUMAN; IMMUNOGENICITY; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 0037300895     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00072-7     Document Type: Review

References (38)

1. Wills RJ, Ferraiolo BL. The role of pharmacokinetics in the development of biotechnologically derived agents. Clin Pharmacokinet 1992;23:406-14.
2. Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 1991;6:133-51.
3. Storm G, Crommelin DJA. Colloidal systems for tumor targeting. Hybridoma 1997;16:119-25.
4. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997;54(Suppl 4):8-14.
5. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998;15:57-88.
6. Fuertges F, Abuchowski A. The clinical efficacy of poly (ethylene glycol) modified proteins. J Controlled Release 1990;11:139-48.
7. Abuchowski A, van es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252:3578-81.
8. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998;1(8):352-8.
9. Reddy KR. Controlled-release pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000;34:915-23.
10. Fung WJ, Porter JE, Bailon P. Strategies for the preparation and characterization of polyethylene conjugated pharmaceutical proteins. Polymer Preprints 1997;38:565-6.
11. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83:601-6.
12. Weider KJ, Palczuk NC, van Es T, et al. Some properties of polyethylene glycol: phenylalanine ammonia-lyase adducts. J Biol Chem 1979;254:12579-87.
13. Abuchowski A, McCoy JR, Palczuk NC. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6.
14. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984;74:36-9.
15. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
16. Working PK, Newman MS, Johnson J, et al. Safety of polyethylene glycol and polyethylene glycol derivatives. Amer Chem Soc Chapter 1997;4:45-57.
17. Liang JT, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
18. Wills RJ, Dennis S, Speigel HE, et al. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther 1984;35:722-7.
19. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990;19:390-9.
20. Nowak MA, Bonhoeffer S, Hill A, et al. Viral dynamics in hepatitis C infection. Proc Natl Acad Sci U S A 1996;93:4398-402.
21. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of IFN-α therapy. Science 1998;282:103-7.
22. O'Brien C, Pockros P, Reddy RK, et al. A double-blind, multicenter, randomized, parallel dose-comparison study of six regimens of 5 kd, linear peginterferon α 2a compared with Roferon-A in patients with chronic hepatitis C. Antiviral Therapy 1999;4(Supp 4):15.
23. Bailon P, Palleroni A, Schaffer CA. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α 2a for treatment of hepatitis C. Bioconjug Chem 2001;12:195-202.
24. Lindsay KL, Trepo C, Heintges T, et al. A randomised, double-blind trial comparing pegylated interferon α 2b to interferon α 2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
25. Zeuzem S, Feinman SV, Raseneck J, et al. Peginterferon α 2a in patients with chronic hepatitis C. N Engl J Med 2000:343:1666-72.
26. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α 2b plus ribavirin compared with interferon α 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
27. Fried M, Schiffman ML, Reddy RK, et al. Pegylated(40 kDa) interferon α 2a in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively controlled, multicenter study. Gastroenterology 2001;120(Suppl):289.
28. Heathcote J, Shiffman ML, Cooksley GE, et al. Peginterferon α 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
29. Bailon P, Spence C, Schaffer CA, et al. Pharmacokinetic properties of five polyethylene glycol conjugates of interferon α 2a. Presented at the Third International Conference of Therapeutics for Viral Hepatitis. Maui, HI, December, 1999.
30. Nieforth KA, Nadeau R, Patel IH, et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon α 2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996;59:636-46.
31. Xu ZX, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α 2a (IFN α 2a) to healthy subjects [abstract]. Hepatology 1998;28:702.
32. Algranati NE, Sy S, Modi M. A branched methoxy 40 kd polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) [abstract]. Hepatology 1999;40:190.
33. Chatelut E, Rostaing L, Gregoire N, et al. A pharmacokinetic model for alfa interferon administered subcutaneously. Br J Clin Pharmacol 1999;47:365-71.
34. Glue P, Fang JWS, Rouzier-Panis R, et al. Pegylated interferon α 2b: pharmacokinetics, pharmacodynamics, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-67.
35. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51.
36. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon α 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
37. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
38. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40 kd) interferon α 2a compared with interferon α 2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.